Overall Survival of Hungarian Cancer Patients Diagnosed Between 2011 and 2019, Based on the Health Insurance Fund Database.

IF 4.5 2区 医学 Q1 ONCOLOGY
Cancers Pub Date : 2025-05-15 DOI:10.3390/cancers17101670
Zoltán Kiss, Tamás László Berki, Anikó Maráz, Zsolt Horváth, Péter Nagy, Ibolya Fábián, Valéria Kovács, György Rokszin, György Surján, Zsófia Barcza, István Kenessey, András Wéber, István Wittmann, Gergő Attila Molnár, Tamás G Szabó, Viktória Buga, Eugenia Karamousouli, Miklós Darida, Zsolt Abonyi-Tóth, Renáta Bertókné Tamás, Viktória Diána Fürtős, Krisztina Bogos, Judit Moldvay, Gabriella Gálffy, Lilla Tamási, Veronika Müller, Zoárd Tibor Krasznai, Gyula Ostoros, Zsolt Pápai-Székely, Gabriella Branyiczkiné Géczy, Lászlóné Hilbert, Csaba Polgár, Zoltán Vokó
{"title":"Overall Survival of Hungarian Cancer Patients Diagnosed Between 2011 and 2019, Based on the Health Insurance Fund Database.","authors":"Zoltán Kiss, Tamás László Berki, Anikó Maráz, Zsolt Horváth, Péter Nagy, Ibolya Fábián, Valéria Kovács, György Rokszin, György Surján, Zsófia Barcza, István Kenessey, András Wéber, István Wittmann, Gergő Attila Molnár, Tamás G Szabó, Viktória Buga, Eugenia Karamousouli, Miklós Darida, Zsolt Abonyi-Tóth, Renáta Bertókné Tamás, Viktória Diána Fürtős, Krisztina Bogos, Judit Moldvay, Gabriella Gálffy, Lilla Tamási, Veronika Müller, Zoárd Tibor Krasznai, Gyula Ostoros, Zsolt Pápai-Székely, Gabriella Branyiczkiné Géczy, Lászlóné Hilbert, Csaba Polgár, Zoltán Vokó","doi":"10.3390/cancers17101670","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Assessing cancer survival trends is crucial for monitoring progress in cancer management and prevention. As part of the broader HUN-CANCER EPI study, this analysis examined overall survival (OS) in the Hungarian cancer population between 2011 and 2019. <b>Methods:</b> Using data extracted from the Hungarian National Health Insurance Fund (NHIF) database, short- and long-term OS were estimated for various cancer types according to age, sex, and diagnostic period using Kaplan-Meier analysis. The study also identified cancer types with significant early mortality following diagnosis. <b>Results:</b> From 2011 to 2019, a total of 528,808 patients were diagnosed with cancer. During the 2015-2019 diagnostic period, the lowest 5-year OS rates were observed for esophageal (7.0%), pancreatic (10.7%), liver (12.5%), gallbladder (13.9%), and lung cancer (18.4%). Conversely, tumor types with better OS included testicular cancer (91.6%), thyroid cancer (89.0%), Hodgkin's lymphoma (84.0%), melanoma (78.6%), and breast cancer (74.1%). A notable proportion of deaths occurred within 2 months of diagnosis for liver (33.2%), pancreatic (27.9%), and gallbladder cancer (29.0%). Significant early mortality within 6 months post-diagnosis was also noted for esophageal (51.3%), stomach (42.9%), and lung cancer (41.7%). <b>Conclusions:</b> The HUN-CANCER EPI study conducted between 2011 and 2019 provides valuable insights into cancer survival patterns in Hungary, emphasizing the importance of early detection and targeted interventions to improve patient outcomes.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 10","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12110003/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17101670","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Assessing cancer survival trends is crucial for monitoring progress in cancer management and prevention. As part of the broader HUN-CANCER EPI study, this analysis examined overall survival (OS) in the Hungarian cancer population between 2011 and 2019. Methods: Using data extracted from the Hungarian National Health Insurance Fund (NHIF) database, short- and long-term OS were estimated for various cancer types according to age, sex, and diagnostic period using Kaplan-Meier analysis. The study also identified cancer types with significant early mortality following diagnosis. Results: From 2011 to 2019, a total of 528,808 patients were diagnosed with cancer. During the 2015-2019 diagnostic period, the lowest 5-year OS rates were observed for esophageal (7.0%), pancreatic (10.7%), liver (12.5%), gallbladder (13.9%), and lung cancer (18.4%). Conversely, tumor types with better OS included testicular cancer (91.6%), thyroid cancer (89.0%), Hodgkin's lymphoma (84.0%), melanoma (78.6%), and breast cancer (74.1%). A notable proportion of deaths occurred within 2 months of diagnosis for liver (33.2%), pancreatic (27.9%), and gallbladder cancer (29.0%). Significant early mortality within 6 months post-diagnosis was also noted for esophageal (51.3%), stomach (42.9%), and lung cancer (41.7%). Conclusions: The HUN-CANCER EPI study conducted between 2011 and 2019 provides valuable insights into cancer survival patterns in Hungary, emphasizing the importance of early detection and targeted interventions to improve patient outcomes.

基于健康保险基金数据库的2011年至2019年匈牙利癌症患者的总体生存率
背景:评估癌症生存趋势对于监测癌症管理和预防进展至关重要。作为更广泛的HUN-CANCER EPI研究的一部分,该分析检查了2011年至2019年匈牙利癌症人群的总生存率(OS)。方法:使用匈牙利国家健康保险基金(NHIF)数据库中提取的数据,采用Kaplan-Meier分析方法,根据年龄、性别和诊断期估计各种癌症类型的短期和长期OS。该研究还确定了诊断后早期死亡率较高的癌症类型。结果:2011年至2019年,共有528,808例患者被诊断为癌症。在2015-2019年诊断期内,食管癌(7.0%)、胰腺癌(10.7%)、肝癌(12.5%)、胆囊癌(13.9%)和肺癌(18.4%)的5年总生存率最低。相反,具有较好OS的肿瘤类型包括睾丸癌(91.6%)、甲状腺癌(89.0%)、霍奇金淋巴瘤(84.0%)、黑色素瘤(78.6%)和乳腺癌(74.1%)。肝癌(33.2%)、胰腺癌(27.9%)和胆囊癌(29.0%)在诊断后2个月内死亡的比例显著。食管癌(51.3%)、胃癌(42.9%)和肺癌(41.7%)在诊断后6个月内也有显著的早期死亡率。结论:2011年至2019年期间进行的HUN-CANCER EPI研究为匈牙利的癌症生存模式提供了有价值的见解,强调了早期发现和有针对性的干预措施对改善患者预后的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancers
Cancers Medicine-Oncology
CiteScore
8.00
自引率
9.60%
发文量
5371
审稿时长
18.07 days
期刊介绍: Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信